GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Change In Receivables

Anxo Pharmaceutical Co (ROCO:6677) Change In Receivables : NT$-43.2 Mil (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Change In Receivables?

Anxo Pharmaceutical Co's change in receivables for the quarter that ended in Jun. 2023 was NT$10.9 Mil. It means Anxo Pharmaceutical Co's Accounts Receivable declined by NT$10.9 Mil from Dec. 2022 to Jun. 2023 .

Anxo Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2022 was NT$-38.6 Mil. It means Anxo Pharmaceutical Co's Accounts Receivable increased by NT$38.6 Mil from Dec. 2021 to Dec. 2022 .

Anxo Pharmaceutical Co's Accounts Receivable for the quarter that ended in Jun. 2023 was NT$199.7 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Anxo Pharmaceutical Co's Days Sales Outstanding for the six months ended in Jun. 2023 was 81.85.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Anxo Pharmaceutical Co's liquidation value for the six months ended in Jun. 2023 was NT$-595.9 Mil.


Anxo Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Anxo Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Change In Receivables Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.29 -32.84 7.08 -36.31 -38.59

Anxo Pharmaceutical Co Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.94 -22.38 15.56 -54.15 10.95

Anxo Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-43.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anxo Pharmaceutical Co  (ROCO:6677) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Anxo Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=199.664/445.186*91
=81.85

2. In Ben Graham's calculation of liquidation value, Anxo Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Anxo Pharmaceutical Co's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=219.665-1096.569+0.75 * 199.664+0.5 * 262.449
=-595.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anxo Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Anxo Pharmaceutical Co (ROCO:6677) Business Description

Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines